Guangzhou Lupeng Pharmaceutical Company Ltd.
Clinical trials sponsored by Guangzhou Lupeng Pharmaceutical Company Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill hopes to tackle tough lymphoma Results expected Mar 2027 (estimated)
- New drug joins standard chemotherapy in fight against B-Cell lymphoma Results expected Jun 2027 (estimated)
-
New drug joins standard chemotherapy in fight against B-Cell lymphoma
Disease control OngoingResearchers are testing whether adding an experimental drug called rocbrutinib to standard R-CHOP chemotherapy is safe and shows early signs of helping adults newly diagnosed with certain B-cell non-Hodgkin lymphomas. The trial enrolls about 112 participants who have not yet rece…
Phase 1 • Sponsor: Guangzhou Lupeng Pharmaceutical Company LTD. • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New pill shows promise for tough blood cancer
Disease control OngoingThis phase 2 trial tests an oral drug called rocbrutinib in 62 people with mantle cell lymphoma that has come back or not responded to other treatments. Participants take the drug once daily until their disease worsens or side effects become too severe. The main goal is to see ho…
Phase 2 • Sponsor: Guangzhou Lupeng Pharmaceutical Company LTD. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC